POGLUT1
Basic information
Region (hg38): 3:119468963-119494708
Previous symbols: [ "C3orf9", "KTELC1" ]
Links
Phenotypes
GenCC
Source:
- Dowling-Degos disease 4 (Moderate), mode of inheritance: AD
- Dowling-Degos disease (Supportive), mode of inheritance: AD
- autosomal recessive limb-girdle muscular dystrophy type 2R1 (Supportive), mode of inheritance: AR
- Dowling-Degos disease 4 (Strong), mode of inheritance: AD
- autosomal recessive limb-girdle muscular dystrophy type 2R1 (Strong), mode of inheritance: AR
- autosomal recessive limb-girdle muscular dystrophy (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Dowling-Degos disease 4; Muscular dystrophy, limb-girdle, autosomal recessive 21 | AD/AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Dermatologic; Musculoskeletal | 21971768; 24387993; 27807076 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (7 variants)
- Dowling-Degos disease 4 (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the POGLUT1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 27 | 31 | ||||
missense | 88 | 95 | ||||
nonsense | 6 | |||||
start loss | 0 | |||||
frameshift | 6 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 3 | |||||
splice region | 5 | 9 | 4 | 18 | ||
non coding | 35 | 25 | 61 | |||
Total | 7 | 6 | 92 | 67 | 30 |
Highest pathogenic variant AF is 0.0000263
Variants in POGLUT1
This is a list of pathogenic ClinVar variants found in the POGLUT1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
3-119469032-G-A | Dowling-Degos disease 4 | Pathogenic/Likely pathogenic (Sep 20, 2022) | ||
3-119469038-G-C | Inborn genetic diseases | Uncertain significance (Mar 01, 2024) | ||
3-119469038-G-T | POGLUT1-related disorder | Uncertain significance (Jan 11, 2023) | ||
3-119469042-G-A | Likely benign (Jan 20, 2023) | |||
3-119469044-C-T | Uncertain significance (Dec 28, 2023) | |||
3-119469048-T-A | Likely benign (Nov 12, 2023) | |||
3-119469059-T-G | Uncertain significance (May 16, 2023) | |||
3-119469064-T-G | Inborn genetic diseases | Uncertain significance (Jul 25, 2023) | ||
3-119469066-G-T | Inborn genetic diseases | Uncertain significance (Aug 08, 2023) | ||
3-119469072-C-T | Likely benign (Mar 18, 2022) | |||
3-119469077-C-T | Inborn genetic diseases | Uncertain significance (Dec 01, 2022) | ||
3-119469086-A-G | Inborn genetic diseases | Uncertain significance (Mar 06, 2023) | ||
3-119469088-G-A | Uncertain significance (May 20, 2023) | |||
3-119469092-G-A | Uncertain significance (Dec 01, 2023) | |||
3-119469099-G-A | Likely benign (Dec 03, 2021) | |||
3-119469114-C-G | Likely benign (Dec 09, 2022) | |||
3-119469123-GCCGAGCCTGCCCCTTGGGCTCGGGGTCTGGCCGGAGTCCCGAGGCGCTCC-G | Likely benign (Oct 04, 2021) | |||
3-119469125-C-G | Likely benign (Jan 19, 2024) | |||
3-119469126-G-A | Likely benign (Oct 30, 2023) | |||
3-119469126-G-T | Benign/Likely benign (Jan 18, 2024) | |||
3-119469238-C-T | Likely benign (May 01, 2023) | |||
3-119469366-G-T | Benign (Jun 20, 2019) | |||
3-119469800-A-G | Likely benign (Oct 22, 2023) | |||
3-119469813-T-C | Likely benign (Oct 17, 2022) | |||
3-119469830-G-C | Uncertain significance (Jan 04, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
POGLUT1 | protein_coding | protein_coding | ENST00000295588 | 11 | 25771 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.56e-8 | 0.956 | 125706 | 0 | 42 | 125748 | 0.000167 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.15 | 164 | 211 | 0.777 | 0.0000107 | 2570 |
Missense in Polyphen | 58 | 82.609 | 0.70211 | 963 | ||
Synonymous | -0.834 | 81 | 72.0 | 1.13 | 0.00000342 | 703 |
Loss of Function | 2.00 | 17 | 28.6 | 0.595 | 0.00000165 | 297 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000630 | 0.000629 |
Ashkenazi Jewish | 0.000203 | 0.000198 |
East Asian | 0.000109 | 0.000109 |
Finnish | 0.0000555 | 0.0000462 |
European (Non-Finnish) | 0.000169 | 0.000167 |
Middle Eastern | 0.000109 | 0.000109 |
South Asian | 0.0000988 | 0.0000980 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Dual specificity glycosyltransferase that catalyzes the transfer of glucose and xylose from UDP-glucose and UDP-xylose, respectively, to a serine residue found in the consensus sequence of C-X-S-X-P-C (PubMed:21081508, PubMed:21490058, PubMed:21949356, PubMed:27807076, PubMed:28775322). Specifically targets extracellular EGF repeats of protein such as CRB2, F7, F9 and NOTCH2 (PubMed:21081508, PubMed:21490058, PubMed:21949356, PubMed:27807076, PubMed:28775322). Acts as a positive regulator of Notch signaling by mediating O-glucosylation of Notch, leading to regulate muscle development (PubMed:27807076). Notch glucosylation does not affect Notch ligand binding (PubMed:21490058). Required during early development to promote gastrulation: acts by mediating O-glucosylation of CRB2, which is required for CRB2 localization to the cell membrane (By similarity). {ECO:0000250|UniProtKB:Q8BYB9, ECO:0000269|PubMed:21081508, ECO:0000269|PubMed:21490058, ECO:0000269|PubMed:21949356, ECO:0000269|PubMed:27807076, ECO:0000269|PubMed:28775322}.;
- Disease
- DISEASE: Limb-girdle muscular dystrophy 2Z (LGMD2Z) [MIM:617232]: A form of autosomal recessive limb-girdle muscular dystrophy, a degenerative myopathy characterized by slowly progressive wasting and weakness of the proximal muscles of arms and legs around the pelvic or shoulder girdles, elevated creatine kinase levels and dystrophic features on muscle biopsy. LGMD2Z is characterized by young-adult onset. {ECO:0000269|PubMed:27807076}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Other types of O-glycan biosynthesis - Homo sapiens (human);Signal Transduction;Pre-NOTCH Processing in the Endoplasmic Reticulum;Pre-NOTCH Expression and Processing;Signaling by NOTCH
(Consensus)
Recessive Scores
- pRec
- 0.107
Intolerance Scores
- loftool
- rvis_EVS
- 0.04
- rvis_percentile_EVS
- 56.92
Haploinsufficiency Scores
- pHI
- 0.128
- hipred
- N
- hipred_score
- 0.488
- ghis
- 0.551
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.114
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Poglut1
- Phenotype
- endocrine/exocrine gland phenotype; growth/size/body region phenotype; liver/biliary system phenotype; embryo phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan);
Gene ontology
- Biological process
- somitogenesis;protein O-linked glycosylation;gastrulation;regulation of gastrulation;protein O-linked glycosylation via serine;positive regulation of Notch signaling pathway;axial mesoderm development;paraxial mesoderm development;muscle tissue development;cardiovascular system development
- Cellular component
- endoplasmic reticulum lumen
- Molecular function
- protein xylosyltransferase activity;UDP-glucosyltransferase activity;UDP-xylosyltransferase activity;glucosyltransferase activity